Victoza (liraglutide) is an injectable medicine for people with type 2 diabetes.
Today, as part of its Single Technology Appraisal (STA) the National Institute forHealth and Clinical Excellence (NICE) published its final guidance on the use of Victoza (liraglutide) for patients with type 2 diabetes in England, Wales and Northern Ireland.
This new guidance is an instruction from NICE to the National Health Service (NHS) to provide mandatory funding for liraglutide. Primary care trusts (PCTs) must find funding for the drug within three months for the appropriate patients as indicated by the guidance.
Dr Marc Evans, Consultant Diabetologist, Llandough Hospital Cardiff, has commented, “Liraglutide represents a valuable option for patients with type 2 diabetes and their healthcare professionals. This is a significant step towards achieving health equality for people in England, Wales and Northern Ireland who qualify for treatment with liraglutide, which now requires mandatory funding from each PCT.”
The guidance recommends once-daily liraglutide 1.2 mg as a clinically and cost effective therapy in combination with two oral anti-diabetic tablets for the control of specific subgroups of people with type 2 diabetes detailed in the guidance. NICE also recommends, irrespective of BMI, that liraglutide 1.2 mg can be used in combination with just one oral anti-diabetic tablet if other tablets are unsuitable in combination with current treatments or cannot be taken due to intolerances.